Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
about
Development, characterization and application of monoclonal antibodies against Brazilian Dengue virus isolatesAn in-depth analysis of original antigenic sin in dengue virus infectionVirus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesStructure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseUnderstanding the dengue viruses and progress towards their controlDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesStructural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic EpitopeStructure of the St. Louis Encephalitis Virus Postfusion Envelope TrimerStructural insights into the neutralization mechanism of a higher primate antibody against dengue virusCrystal Structure of the Japanese Encephalitis Virus Envelope ProteinStructural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-ReactivityThe structural basis for serotype-specific neutralization of dengue virus by a human antibodyDengue: knowledge gaps, unmet needs, and research prioritiesCharacterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies.Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Structural, antigenic, and evolutionary characterizations of the envelope protein of newly emerging Duck Tembusu Virus.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assayDevelopment and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccineCorrelation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.Dissection of antibody specificities induced by yellow fever vaccinationAntibody-mediated neutralization of flaviviruses: a reductionist view.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISADirected evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III.The Molecular Epidemiology and Evolution of Murray Valley Encephalitis Virus: Recent Emergence of Distinct Sub-lineages of the Dominant Genotype 1.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virionsGenotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization.A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.
P2860
Q24288673-8913AFE0-458E-4F01-A6BF-FAD37109E94DQ24606493-4A833D15-A524-4914-97D1-6882C859DB2FQ26314715-9F26BB6B-5198-47B8-B2DC-EE41CDCD7967Q26700120-B22101D1-65F6-4CCD-BFB7-B263DAF18D74Q26995782-49CECB29-A483-4B04-BE27-8C31A59398AAQ27011587-77212CEC-E1CB-48AC-9F11-160836CBCFCBQ27304342-935CD03B-4AB8-45DE-A15B-B39E6B48FFCAQ27674417-03ADB25B-F591-4BF9-A47C-0A33735C5ACDQ27674868-418C620A-F0E1-43C0-8E3A-E8321CF03FC6Q27675965-22328A7E-BB4D-4F7C-B085-D517E395A3C5Q27676100-6CA82670-80A1-4465-A060-71D1FEB560F8Q27678419-D54FB682-ACF5-4AE5-A396-A5564500B7B9Q27681306-AE3A913C-BABD-4888-A111-87242D444ECDQ28729764-9865F5F8-0F7D-4B25-8278-28308B48449EQ30145645-EF0B9D13-E879-4FBB-8C01-845FAE418785Q30395028-563D5BF9-D48D-4247-A738-A6B8FF93A72FQ31131254-0F364AD9-732C-44F2-BF35-C4A5E13A0BB5Q33425879-FA87E918-81B2-4560-89AF-8D839326D415Q34123956-364B23C0-7D78-474D-95DB-7F57352F12F1Q34184711-8E07F100-D292-47C3-8855-46D3C96CB755Q34262245-87E58B13-5721-4AD1-8716-D1DAB645B7D6Q34779065-D17C895E-0D46-454B-94FB-81EF759D2D89Q34789343-ECF0D84C-C468-4E6E-B402-3C191680569FQ34999617-E9A6A8D2-AF19-44E0-9C78-7135C41F66FCQ35069160-38B7F058-4D4A-466D-B4D8-7DAF13813DFEQ35081258-D3F079F3-FB89-449E-9ED6-65BE357C6E33Q35092308-90DFCB77-7A90-4307-9ED3-020CB9BB1312Q35152094-388478C7-37B7-4E32-8297-5E6468A440CCQ35681101-B935EA5D-9E33-4A33-A1DE-5324C9F3D792Q35756190-69778151-85C1-4072-B2E1-EDEAB643297BQ35764445-DA9F105A-98E1-45C5-93E2-25A1BA16D34EQ35796610-EF911541-9A9E-43A0-8B04-11964FC5F694Q35850813-2E73C640-172B-4EFC-8BFA-2519B695F733Q35982791-7D23FC90-9356-4943-B64A-C195E9792E4BQ36245225-E7EEA952-2D2D-4B6A-959F-2E9C5D9879CDQ36286276-7EE59A41-E28F-4F5C-A5CF-9941C9270020Q36597801-5A64A5BB-2375-45F4-AC61-ADD2AC2F99A6Q36607383-ADE4E9FB-C9E4-4C18-999A-94543583B94CQ36667964-4F0334AC-6C08-4BF4-A9A7-6608C78F943EQ37012203-5E81771D-A4A8-4A31-B5BB-DC05F1258C24
P2860
Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Genotype-specific neutralizati ...... s against dengue virus type 3.
@en
Genotype-specific neutralizati ...... s against dengue virus type 3.
@nl
type
label
Genotype-specific neutralizati ...... s against dengue virus type 3.
@en
Genotype-specific neutralizati ...... s against dengue virus type 3.
@nl
prefLabel
Genotype-specific neutralizati ...... s against dengue virus type 3.
@en
Genotype-specific neutralizati ...... s against dengue virus type 3.
@nl
P2093
P2860
P356
P1433
P1476
Genotype-specific neutralizati ...... s against dengue virus type 3.
@en
P2093
Daved H Fremont
James D Brien
Katie M O'Brien
S Kyle Austin
Syd Johnson
P2860
P304
10630-10643
P356
10.1128/JVI.01190-10
P407
P5008
P577
2010-08-11T00:00:00Z